Shirish M. Gadgeel MBBS, comments on significant studies in ALK+ NSCLC from ESMO 2019

Shirish M. Gadgeel MBBS, Mary Lou Kennedy Research Professor in Thoracic Oncology, Co-leader, Thoracic Oncology Research Program, University of Michigan, Rogel Cancer Center, elaborates on significant studies in ALK+ non-small cell lung cancer (NSCLC) presented at the 2019 ESMO World Congress

Shirish M. Gadgeel MBBS, Mary Lou Kennedy Research Professor in Thoracic Oncology, Co-leader, Thoracic Oncology Research Program, University of Michigan, ...

Véronique Diéras, MD, on the optimal setting in which to receive a PARP inhibitor

Dr. Diéras, Senior Medical Oncologist, Head, Breast Cancer Group, Department of Medical Oncology, Centre Eugène Marquis, Rennes, France, tells us about the setting in which a metastatic breast cancer patients should receive a PARP inhibitor

Dr. Diéras, Senior Medical Oncologist, Head, Breast Cancer Group, Department of Medical Oncology, Centre Eugène Marquis, Rennes, France, tells us ...

Robert L. Coleman, MD, FACOG, FACS, on takeaways from the ovarian plenary session at ESMO '19

Dr. Coleman, Professor, Department of Gynecologic Oncology and Reproductive Medicine, Ann Rife Cox Chair in Gynecology, MD Anderson Cancer Center, comments on key takeaways from the ovarian plenary session at the 2019 ESMO World Congress

Dr. Coleman, Professor, Department of Gynecologic Oncology and Reproductive Medicine, Ann Rife Cox Chair in Gynecology, MD Anderson Cancer Center, ...

Amer Zeidan, MBBS, comments on the influx of investigational oral agents in myeloid malignancies

Amer Zeidan, MBBS, Associate Professor of Hematology, Yale School of Medicine, Yale Cancer Center, comments on the influx of investigational oral agents in myeloid malignancies and elaborates on some of the important studies underway with HMA therapy in acute myeloid leukemia (AML)

Amer Zeidan, MBBS, Associate Professor of Hematology, Yale School of Medicine, Yale Cancer Center, comments on the influx of investigational ...

Arndt Vogel, MD, elaborates on some of the key takeaways from the GO30140 trial

Dr. Vogel, Professor of Gastrointestinal Oncology in the Department of Gastroenterology, Hepatology and Endocrinology, Managing Senior Consultant, Hannover Medical School, elaborates on some of the key takeaways from GO30140, the multi-cohort phase I study investigating combination atezolizumab and bevacizumab in 1st line hepatocellular carcinoma (HCC)

Dr. Vogel, Professor of Gastrointestinal Oncology in the Department of Gastroenterology, Hepatology and Endocrinology, Managing Senior Consultant, Hannover Medical School, ...

George Sledge, MD, explains how MONARCH-2 may impact the current standard of care

Dr. Sledge, Professor and Chief, Division of Oncology, Stanford Cancer Center, Stanford University School of Medicine, explains how the results from the MONARCH-2 trial may impact the current standard of care

Dr. Sledge, Professor and Chief, Division of Oncology, Stanford Cancer Center, Stanford University School of Medicine, explains how the results ...

Dennis J. Slamon, MD, PhD, discusses implications from the MONALEESA-3 trial

Dr. Slamon, Professor and Chief of Hematology/Oncology, UCLA Department of Medicine, Director of Clinical/Translational Research, Director of the Revlon/UCLA Women's Cancer Research Program at Jonsson Comprehensive Cancer Center, discusses the implications from the phase III MONALEESA-3 trial for postmenopausal women with HR+ and HER2 negative advanced breast cancer

Dr. Slamon, Professor and Chief of Hematology/Oncology, UCLA Department of Medicine, Director of Clinical/Translational Research, Director of the Revlon/UCLA Women's ...

Nader Sanai, MD, offers perspective on the challenges in treating glioblastoma

Dr. Sanai, Department of Neurosurgery, Director, Ivy Brain Tumor Center, offers perspective on some of the challenges in treating and managing recurrent glioblastoma

Dr. Sanai, Department of Neurosurgery, Director, Ivy Brain Tumor Center, offers perspective on some of the challenges in treating and ...

Christian Rolfo, MD, PhD, MBA, on the role of liquid biopsy in the treatment of lung cancer

Dr. Rolfo, Professor, Oncology, Director, Thoracic Medical Oncology and Early Clinical Trials, University of Maryland, Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, explains the value and role of liquid biopsy in the treatment of lung cancer

Dr. Rolfo, Professor, Oncology, Director, Thoracic Medical Oncology and Early Clinical Trials, University of Maryland, Marlene and Stewart Greenebaum Comprehensive ...

Ulrik Lassen, MD, PhD, on whether testing for TRK fusion is easy and reliable

Dr. Lassen, Professor, Medical Oncology; Head, Department of Oncology, Rigshospitalet, Copenhagen, Denmark, elaborates on whether it is easy and reliable to test for TRK fusion

Dr. Lassen, Professor, Medical Oncology; Head, Department of Oncology, Rigshospitalet, Copenhagen, Denmark, elaborates on whether it is easy and reliable ...